Navigation Links
Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
Date:5/28/2009

Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe, according to Millennium Research Group

WALTHAM, Mass., May 28 /PRNewswire/ -- According to Millennium Research Group's (MRG's) European Markets for Peripheral Vascular (PV) Devices 2009 report, rapid growth in the number of endovascular procedures that treat lower extremity peripheral artery disease in Europe is being fueled by positive clinical trial results, increased competitor focus, and the release of new drug-eluting devices for these indications. Combined, these factors will drive the markets for lower extremity PV stents and percutaneous transluminal angioplasty (PTA) balloon catheters to reach combined revenues in excess of $180 million by 2013.

The number of endovascular femoropopliteal (fem-pop) procedures performed in Europe is experiencing double-digit year-over-year growth, driven primarily by positive data released from clinical trials such as Cordis' SIROCCO and Edwards Lifesciences' RESILIENT. The positive results from these trials have demonstrated both promising patency rates and reduced stent fracture rates, which will continue to bolster physician confidence in fem-pop stenting. Fem-pop PTA procedure volumes in Europe will grow in tandem with fem-pop stenting, which often involves predilation of the lesion or postdilation of the stent using PTA balloon catheters. As a result, most major PV stent manufacturers are now focusing on the fem-pop indication for technology development and marketing.

"Endovascular infrapopliteal procedures, which treat below-the-knee peripheral artery disease, are also growing rapidly," says Stephanie Labelle, Senior Analyst at MRG. "Although revenues in both the PV stent and PTA balloon catheter markets were relatively small for the infrapopliteal indication in 2008, infrapopliteal procedures will continue to outgrow other PV stenting indications through 2013. In addition, the introduction of drug-eluting stents and balloons indicated for infrapopliteal procedures will generate a considerable amount of physician excitement, which will help to boost market revenues over the years to come."

MRG's European Markets for Peripheral Vascular Devices 2009 report provides coverage of key industry competitors, including Abbott Vascular, Boston Scientific, Cook Medical, Cordis, C. R. Bard, Medtronic Vascular, Terumo Medical, W. L. Gore, and many more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
2. AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
3. New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
4. Experience Not Always the Best Prescription for Snowblowers
5. Statins Lower Stroke Severity, Improve Recovery
6. Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet
7. AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
8. Implantable Defibrillators Lower Risk of Death in Older Heart Patients
9. Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Want a Reason to Love Your Lower Belly Fat? Its Rich in Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ... diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für das ... mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu ... und Aktualisierung zum Wachstum" finden Sie hier ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... ... 2017 , ... New Jersey ranks among the top five states in the ... need for advanced services is growing. , Project WE vs C is a ... with their non-profit partners in their fight against cancer and in support of their ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is linked ... LRRK2 mutation, according to a study released today at the 1st Pan American ... link between pesticides and incidence of sporadic PD through occupational exposure. This latest ...
Breaking Medicine News(10 mins):